SILVER SPRING, Md., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Richard M. Hyslop, Ph.D. has agreed to join the Scientific Advisory Board of Medical Marijuana Sciences, Inc., a wholly-owned subsidiary of Nuvilex, Inc.
Dr. Hyslop, Professor of Chemistry and Biochemistry at the University of Northern Colorado, is the first member of the Scientific Advisory Board of Medical Marijuana Sciences recruited by the Board's Chairman, Mark L. Rabe, MD. Dr. Hyslop obtained his Ph.D. degree in biochemistry from the University of Texas. His areas of expertise include anti-cancer drug design, the metabolism of anti-cancer drugs and studies of enzymes and enzyme-catalyzed reactions in biological tissues.
Dr. Rabe believes that Dr. Hyslop's experience with cancer drugs and enzymology will prove to be invaluable in pursuing the goals of Medical Marijuana Sciences that include developing treatments, which employ constituents of Cannabis together with the Cell-in-a-Box™ cellulose-based live-cell encapsulation technology, for some of the deadliest forms of cancer. His location in Colorado, one of the states that have legalized the use of marijuana for medicinal purposes, is anticipated to facilitate Dr. Hyslop's efforts in this regard, according to Dr. Rabe.
Nuvilex's Chief Operating Officer, Dr. Gerry Crabtree commented "Dr. Rabe's recruitment of Dr. Hyslop is an important first step in building a Scientific Advisory Board for Medical Marijuana Sciences that is diverse in terms of talent and that we believe will play a very important role in the development of Nuvilex as a whole. Dr. Hyslop's recruitment was accomplished in a very short time after Dr. Rabe's appointment as the Board's Chairman, and we expect additional members to be added to the Board in the relatively near future."
Nuvilex is a biotechnology company with the rights to a novel cellulose-based live-cell encapsulation technology, called Cell-in-a-Box™, that will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and diabetes are being built. The Company's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon the well-known chemical constituents of marijuana. Nuvilex is exploring ways in which the Cell-in-a-Box™ technology may play a role in these efforts.
This press release may contain forward-looking statements regarding Nuvilex and its future events and results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding Nuvilex's financial position, business strategy, plans and objectives of management for future operations and business conditions are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties. Important factors, many of which are beyond the control of Nuvilex, that could cause actual results to differ materially from those set forth in the forward-looking statements include general economic or business conditions; changes in legislation or regulatory requirements; conditions of the securities markets; Nuvilex's ability to raise capital; changes in accounting principles, policies or guidelines; financial or political instability; and other economic, competitive, governmental, regulatory and technical factors affecting the plans, operations, products and services of Nuvilex and its subsidiaries.
Nuvilex has based these forward-looking statements on its current expectations and assumptions about future events. While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond the control of Nuvilex. Nuvilex does not assume any obligations to update any of these forward-looking statements.
More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting Investor Relations.
CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 firstname.lastname@example.org